Integral Health Asset Management’s Akero Therapeutics AKRO Stock Holding History

Integral Health Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$5.06M	–	70
2023 Q3	$5.06M	Buy	100,000 +30,000	+43%	+$1.4M	0.7%	51
2023 Q2	$3.27M	Hold	70,000	–	–	0.4%	64
2023 Q1	$2.68M	Hold	70,000	–	–	0.54%	56
2022 Q4	$3.84M	Sell	70,000 -160,000	-70%	-$6.86M	0.81%	44
2022 Q3	$7.83M	Sell	230,000 -58,058	-20%	-$888K	1.52%	26
2022 Q2	$2.72M	Buy	288,058 +88,058	+44%	+$918K	0.56%	53
2022 Q1	$2.84M	Buy	200,000 +115,000	+135%	+$2.01M	0.74%	48
2021 Q4	$1.8M	Hold	85,000	–	–	0.5%	56
2021 Q3	$1.9M	Hold	85,000	–	–	0.55%	55
2021 Q2	$2.11M	Hold	85,000	–	–	0.58%	50
2021 Q1	$2.47M	Hold	85,000	–	–	0.7%	47
2020 Q4	$2.19M	Hold	85,000	–	–	0.65%	44
2020 Q3	$2.62M	Buy	+85,000	New	+$2.97M	0.8%	46
2020 Q2	–	Sell	-60,000	Closed	-$1.27M	–	61
2020 Q1	$1.27M	Buy	+60,000	New	+$1.29M	0.56%	48

Other funds holding AKRO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Integral Health Asset Management's AKRO Position: Q4 2023 in Review

Integral Health Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 100,000 shares — an estimated $5.06M sold.

Integral Health Asset Management first reported a position in AKRO in Q1 2020 and held it in 14 quarters. The position peaked at $7.83M in Q3 2022. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

Integral Health Asset Management reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
Integral Health Asset Management sold 100,000 Akero Therapeutics shares in Q4 2023, an estimated $5.06M.
Integral Health Asset Management first reported a position in Akero Therapeutics in Q1 2020 and held it in 14 quarters.
Integral Health Asset Management's Akero Therapeutics position peaked at $7.83M in Q3 2022.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Integral Health Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.